MEDI6012
Phase 2Small molecule
AstraZenecaMEDI6012 is one of 105 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 2.
3
Indications
4
Total Trials
0
Active Trials
104
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Spiriva
Boehringer IngelheimPhase 3
Xarelto
WWim Janssens
Phase 3
Retatrutide
Eli LillyPhase 3
Maridebart Cafraglutide
AmgenPhase 3
Tryngolza (autoinjector)
Ionis PharmaceuticalsPhase 3
Repatha
AmgenPreclinical
Benicar
NovartisPreclinical
Farxiga
AstraZenecaPreclinical
Mounjaro
Eli LillyPreclinical
Praluent
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metabolism1 trial
Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism
Terminated·—·Phase 2·NCT03773172·7 enrolled
Coronary Artery Disease1 trial
Cardiovascular Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MEDI6012. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company